Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study

被引：0
|
作者：
Zoghbi, Marianne [1 ]
Jabbour, Elias [1 ]
Haddad, Fadi [1 ]
Short, Nicholas James [1 ]
Senapati, Jayastu [1 ]
Macaron, Walid [1 ]
Nasnas, Cedric Christophe [1 ]
Nasr, Lewis Fady [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Wierda, William G. [1 ]
Borthakur, Gautam [1 ]
Bravo, Guillermo Montalban [1 ]
Ravandi, Farhad [1 ]
Garcia-Manero, Guillermo [1 ]
Kadia, Tapan M. [1 ]
Chien, Kelly Sharon [1 ]
Thankachan, Jennifer [1 ]
Garris, Rebecca [1 ]
Kantarjian, Hagop M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19039
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL): The Venda Trial, in Progress
    Leonard, Jessica T.
    Cook, Rachel
    Newell, Laura F.
    Gandhi, Arpita
    Swords, Ronan T.
    Eide, Christopher A.
    Hayes-Lattin, Brandon
    Johnson, Kara
    Traer, Elie
    Kurtz, Stephen E.
    Saultz, Jennifer N.
    Tognon, Cristina
    Tyner, Jeffrey W.
    Lachowiez, Curtis A.
    BLOOD, 2023, 142
  • [42] CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
    Rafei, Hind
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Khoury, Joseph D.
    Wang, Sa A.
    Jorgensen, Jeffrey L.
    Khouri, Issa F.
    Kebriaei, Partow
    Jain, Nitin
    Dabaja, Bouthaina S.
    Masarova, Lucia
    Kadia, Tapan M.
    Paul, Shilpa
    Nichols, Dan
    Garcia-Manero, Guillermo
    Burger, Jan A.
    DiNardo, Courtney D.
    Daver, Naval
    Montalban-Bravo, Guillermo
    Yilmaz, Musa
    Bose, Prithviraj
    Khouri, Rita
    Thompson, Philip A.
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    Konopleva, Marina
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [43] Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study
    Rafei, Hind
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Khoury, Joseph D.
    Wang, Sa A.
    Jorgensen, Jeffrey L.
    Khouri, Issa F.
    Kebriaei, Partow
    Champlin, Richard E.
    Jain, Nitin
    Dabaja, Bouthaina S.
    Issa, Ghayas C.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Paul, Shilpa
    Jammal, Nadya
    Garcia-Manero, Guillermo
    Wierda, William G.
    DiNardo, Courtney D.
    Daver, Naval
    Montalban-Bravo, Guillermo
    Khouri, Rita
    Nasnas, Patrice
    Thompson, Philip A.
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    Konopleva, Marina
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [44] A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS
    Bassan, R.
    Fumagalli, M.
    Meloni, G.
    Audisio, E.
    Cascavilla, N.
    Paolini, S.
    Specchia, G.
    Cerqui, E.
    Mico, C.
    Fabbiano, F.
    Ronco, F.
    Scattolin, A. M.
    Perfetti, P.
    Paoloni, F.
    Vitale, A.
    Vignetti, M.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 199 - 199
  • [45] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kim, Kunhwa
    Kantarjian, Hagop
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas J.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Chien, Kelly S.
    Daver, Naval
    Pemmaraju, Naveen
    Jain, Nitin
    Adewale, Lade
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Verstovsek, Srdan
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [46] Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse
    Sasaki, Koji
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Short, Nicholas J.
    Kebriaei, Partow
    Huang, Xuelin
    Rytting, Michael E.
    Jain, Nitin
    Konopleva, Marina Y.
    Garcia-Manero, Guillermo
    Champlin, Richard E.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Estrov, Zeev E.
    Takahashi, Koichi
    Loiselle, Christopher
    Encarnacion, Corabelle
    Rostykus, Meagan
    Khouri, Rita
    Nasnas, Patrice
    Jacob, Jovitta
    Kwari, Monica
    Garris, Rebecca
    Jabbour, Elias
    BLOOD, 2019, 134
  • [47] Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    O'Brien, Susan
    Sasaki, Koji
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Jacob, Jovitta
    Garris, Rebecca
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [48] Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    O'Brien, Susan
    Ravandi, Farhad
    Short, Nicholas
    Thomas, Deborah
    Garcia-Manero, Guillermo
    Daver, Naval
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Sasaki, Koji
    Pemmaraju, Naveen
    Alvarado, Yesid
    Jacob, Jovitta
    Garris, Rebecca
    Thompson, Philip
    Cortes, Jorge
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S255 - S256
  • [49] Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
    Ravandi, Farhad
    Thomas, Deborah
    Kantarjian, Hagop
    Faderl, Stefan
    Koller, Charles
    Dara, Samuel
    Garris, Rebecca
    Kebriaei, Partow
    Borthakur, Gautam
    Wierda, William
    Burger, Jan
    Cortes, Jorge
    O'Brien, Susan
    BLOOD, 2008, 112 (11) : 1005 - 1005
  • [50] Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib
    Wassmann, B
    Pfeifer, H
    Scheuring, UJ
    Binckebanck, A
    Gökbuget, N
    Atta, J
    Brück, P
    Rieder, H
    Schoch, C
    Leimer, L
    Schwerdtfeger, R
    Ehninger, G
    Lipp, T
    Perz, J
    Stelljes, M
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2004, 103 (04) : 1495 - 1498
12345